FROGGER'S HIDEOUT

[OCKHAM'S RAZOR]

GNBT 605K VOLUME 10 DAY AVG_609K .0063 +12.50%



GNBT entered the MMJ sector when they announced that it has acquired a substantial minority equity stake in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.

Read about the partnership
http://investor.generex.com/releasedetail.cfm?ReleaseID=929931

http://www.cannsci.com/company/

GNBT TECHNOLOGY
*The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.


GNBT has products in PHASE II & III
http://generex.com/pipeline_en_245cms.htm
PARTNERS:
http://www.generex.com/partners_en_246cms.htm